Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer

Abstract

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. March 29, 2023 Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. March 29, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02784 Journal of Clinical Oncology - published online before print March 29, 2023 PMID: 36989608 Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer Clifford A. Hudis , MD1,2xClifford A. HudisSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2American Society of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02784 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 1998, with the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18, Fisher et al1 demonstrated that preoperative (earlier) use of conventional postoperative adjuvant therapy did not improve or diminish overall outcomes (disease-free and overall survival) in early-stage breast cancer. In 2008, Liedtke et al2 suggested that response (specifically failure to achieve a pathologic complete response) after preoperative therapy could identify those patients with poor prognosis triple-negative disease who would have worse long-term outcomes. The impact of these studies today is that we can offer preoperative therapy where it is needed knowing it is safe and effective, and we can use this setting to help accelerate the pace of research.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Clifford A. HudisUncompensated Relationships: Alliance Foundation Trials, Columbia University, Memorial Sloan-Kettering Cancer CenterOpen Payments Link: https://openpaymentsdata.cms.gov/physician/471974No other potential conflicts of interest were reported. Companion Effect of preoperative chemotherapy on the outcome of women with operable breast cancer Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer